AUROBINDO

September 22, 2022

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/ Madam,

Sub: Completion of US FDA Inspection at Raleigh Plant, North Carolina, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company

Ref: Our Letter dated August 29, 2022

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to our above referred letter, this is to inform you that:

The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, has received an establishment inspection report (EIR) mentioning the inspection a voluntary action initiated (VAI) from the United States Food and Drug Administration (US FDA) and with this, the US FDA pre-approval inspection and GMP inspection are concluded.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

ADIREDDY BADDIGAM
Digitally signed by ADIREDDY BADDIGAM
Date: 2022.09.22 10:33:59 +05'30'

B. Adi Reddy
Company Secretary